Gilead Sciences, Inc. (NASDAQ:GILD) shares are trading lower in Tuesday’s after-hours session after the company reported weak earnings results and issued soft guidance.
Q4 Revenue: $7.1 billion, in line with estimates
Q4 EPS: $1.72, missed estimates of $1.76
Total revenues were down 4% in the fourth quarter, primarily due to lower Veklury (remdesivir) and HIV sales. The company said earnings were impacted by higher total costs and expenses and lower Veklury revenues.
Gilead generated $2.2 billion in operating cash flow during the quarter. The company used …